What question did this study set out to answer?

To evaluate the efficacy and safety of adding acalabrutinib to bendamustine-rituximab as a first-line treatment regimen for older adults with untreated mantle cell lymphoma.

May 1, 2025Journal of Clinical OncologyOpen Access

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

MWMichael Wang MWMichael Wang DBDavid Belada

Discussion

Member takes

Overview

Randomized trial reveals improved progression-free survival with acalabrutinib and bendamustine-rituximab in untreated mantle cell lymphoma, indicating a potent first-line treatment option.

Key Points

To evaluate the efficacy and safety of adding acalabrutinib to bendamustine-rituximab as a first-line treatment regimen for older adults with untreated mantle cell lymphoma.
Randomized, double-blind trial assigning 598 previously untreated mantle cell lymphoma patients aged 65 years and older to acalabrutinib or placebo plus bendamustine-rituximab (N=299 per arm).
Patients received acalabrutinib (100 mg twice daily) or placebo alongside six cycles of bendamustine and rituximab, followed by two years of maintenance rituximab in responders with a median follow-up of 49.8 months.
Median progression-free survival was significantly prolonged with acalabrutinib compared to placebo (66.4 vs. 49.6 months; HR, 0.73 [95% CI, 0.57 to 0.94]; P = .0160).
Overall response and complete response rates were 91.0% and 66.6% in the acalabrutinib arm versus 88.0% and 53.5% in the placebo arm, while overall survival did not differ significantly (HR, 0.86 [95% CI, 0.65 to 1.13]; P = .27).
Grade 3 or greater adverse events occurred in 88.9% of patients in the acalabrutinib group and 88.2% in the placebo group.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/6a7154d435aa2c282ce2a361 https://doi.org/10.1200/jco-25-00690

View Full Paper

Ask AI

Bookmark

May 1, 2025Journal of Clinical OncologyOpen Access

Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma

View Full Paper

Ask AI

Bookmark

Authors

MWMichael Wang MWMichael Wang DBDavid Belada

Discussion

Member takes

Overview

Randomized trial reveals improved progression-free survival with acalabrutinib and bendamustine-rituximab in untreated mantle cell lymphoma, indicating a potent first-line treatment option.

Key Points

To evaluate the efficacy and safety of adding acalabrutinib to bendamustine-rituximab as a first-line treatment regimen for older adults with untreated mantle cell lymphoma.
Randomized, double-blind trial assigning 598 previously untreated mantle cell lymphoma patients aged 65 years and older to acalabrutinib or placebo plus bendamustine-rituximab (N=299 per arm).
Patients received acalabrutinib (100 mg twice daily) or placebo alongside six cycles of bendamustine and rituximab, followed by two years of maintenance rituximab in responders with a median follow-up of 49.8 months.
Median progression-free survival was significantly prolonged with acalabrutinib compared to placebo (66.4 vs. 49.6 months; HR, 0.73 [95% CI, 0.57 to 0.94]; P = .0160).
Overall response and complete response rates were 91.0% and 66.6% in the acalabrutinib arm versus 88.0% and 53.5% in the placebo arm, while overall survival did not differ significantly (HR, 0.86 [95% CI, 0.65 to 1.13]; P = .27).
Grade 3 or greater adverse events occurred in 88.9% of patients in the acalabrutinib group and 88.2% in the placebo group.

Cite This Study

Wang et al. (2025) studied this question.

synapsesocial.com/papers/6a7154d435aa2c282ce2a361 https://doi.org/10.1200/jco-25-00690

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark